Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | UTRN | P46939 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615447 | 0.89 | APP (0.55) | APPMAPTALDH1A1GAAHPGD | |
| SCHEMBL1615288 | 0.87 | APP (0.57) | APPMAPTALDH1A1GAAHPGD | |
| SCHEMBL13351692 | 0.81 | MAOB (0.70) | APPMAPTALDH1A1MAOBSMN1; SMN2 | |
| SCHEMBL1614965 | 0.78 | APP (0.61) | APPMAPTALDH1A1GAAHPGD | |
| SCHEMBL31330488 | 0.74 | HTR1A (0.55) | TLR8 | |
| SCHEMBL1615295 | 0.74 | APP (0.56) | APPMAPTALDH1A1GAAHPGD | |
| SCHEMBL1614841 | 0.72 | APP (0.69) | APPMAPTALDH1A1HPGDMAOB | |
| SCHEMBL1508054 | 0.71 | APP (0.63) | APPALDH1A1HPGDMAOBSMN1; SMN2 | |
| SCHEMBL1615277 | 0.70 | APP (0.66) | APPMAPTALDH1A1HPGDMAOB | |
| SCHEMBL1614949 | 0.67 | APP (0.61) | APPMAPTALDH1A1HPGDMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | claimed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | claimed |
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2300481-B1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530483-B2 | Substituted azabenzoxazoles | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME LLC | 2011-04-14 | — | — | US | disclosed |
| WO-2010051196-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009155017-A2 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110085985-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | APBA1, APP, BACE1 | APP 2/4885MAPT 23/4885ALDH1A1 2376/4885 |
| US-20110212031-A1 | NOVEL SUBSTITUTED AZABENZOXAZOLES | MAOB, MAOA, AANAT | APP 73/4885MAPT 107/4885ALDH1A1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.